Arch Biopartners Provides MetaMx Development Update
TORONTO, ONTARIO--(Marketwired - Dec. 1, 2015) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced it has successfully completed quality control and pre-clinical validation of a synthesis of MetaMx™ which was produced by a third party chemistry manufacturer in the U.S.
Arch Biopartners Receives Orphan Drug Designation from FDA for AB569
TORONTO, ONTARIO--(Marketwired - Nov. 13, 2015) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company focused on developing innovative technologies that make a significant clinical impact on patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for AB569 in the treatment of Pseudomonasaeruginosa (P. aeruginosa) pulmonary infections in patients with cystic fibrosis.
Arch Biopartners Retains Virtus Advisory to Provide Investor Relations Services
TORONTO, ONTARIO--(Marketwired - Oct. 21, 2015) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), today announced that it has retained Virtus Advisory Group Inc. ("Virtus"), to develop and implement a strategic investor relations program, which includes enhancing the Company's exposure among industry stakeholders and investors across Canada.